Print
What the CIA Knew In 1951 And Why You Were Never Told
Every once in a while, a piece of paper tumbles out of the government’s filing cabinet and exposes just how long the truth has been kept on ice.
That’s what’s happening right now with a 1951 CIA report called “Biochemical Resemblance Between Endoparasites and Malignant Tumors,” quietly declassified years ago and only now exploding across social media. It summarizes Soviet research that saw something modern medicine still won’t talk about: cancer cells and parasitic worms behaving like biological twins, feeding on sugar, thriving in low‑oxygen environments, and responding to the same types of chemicals.
And instead of sounding an international alarm and urgently testing cheap anti‑parasitic compounds as potential cancer treatments, U.S. intelligence classified the report and sat on it for six decades. That’s not “oops, we misplaced it.” That’s a decision. A choice. And the human cost of that choice is written in the cemeteries of every nation on earth.
A System Built to Profit from Sickness, Not Health
In the 1950s, the CIA wasn’t just spying on Soviet missiles; it was tracking Soviet science, including early cancer research that might have military or medical implications.
The Alpatov paper they translated described tumors and endoparasites as metabolically similar: both could survive in oxygen‑poor conditions and both hoarded glycogen, a concentrated energy reserve inside tissue.
Those similarities opened the door to one obvious, explosive possibility—if parasites and tumors share metabolic vulnerabilities, then compounds that kill parasites might also cripple cancer.
But instead of that idea becoming front‑page news, it went into a CIA folder stamped “confidential.” Meanwhile, the “standard of care” in oncology evolved into a multi‑billion‑dollar industry of patented drugs, radiation machines, and long, profitable treatment cycles. There’s no financial incentive for anyone at the top to admit that dirt‑cheap off‑patent parasite pills might have been a missing piece all along.
There is, however, every incentive to keep the conversation narrowly fenced in: chemo, radiation, surgery—take it or leave it.
While They Locked It Up, Real People Paid the Price
That brings us to the man in Canada, sitting in an oncologist’s office with a stage‑four pancreatic cancer diagnosis hanging over his head like a death sentence.
His doctors told him what millions have heard before: the best they could offer was palliative chemotherapy, not to cure him, but to maybe stretch out his remaining time by a few months.
At the same time, because this was Canada, the system quietly placed another option on the table—MAID, Medical Assistance in Dying, the government‑approved exit door for people the medical machine has already written off.
Two files, two paths: a few brutal months on chemo, or a scheduled, clinical death. That’s what the “healthcare” system had ready for him. Not questions. Not curiosity. Not, “What else could we try?” Just a form of managed surrender.
One Family’s Revolt Against the Script
But one of his family members refused to play along. Furious at how casually death had been normalized, this relative started digging—late‑night searches, obscure forums, interviews with doctors who’d been smeared or silenced for talking about alternative therapies.
That’s how they landed on fenbendazole, a broad‑spectrum dewormer usually used on animals, chemically close to the human anti‑parasitic mebendazole.
They started him on fenbendazole. Quietly. Carefully. Then they added ivermectin, another off‑patent anti‑parasitic that’s been relentlessly attacked in the media ever since people noticed it might help more than pharmaceutical gatekeepers were comfortable admitting.
And while the hospital waited for him to show up for chemo and euthanasia, his family chose a third path the system refuses to acknowledge: fight back with the very class of drugs that 1950s scientists—and that buried CIA file—suggested might hit tumors where it hurts.
Four Months, Then a Shock the Oncologist Didn’t Expect
The next four to five months were not Hollywood‑style miracle scenes. They were slow, anxious, and gritty: pills, side‑effects, worry, and the patient trying to live day to day with a diagnosis most people never outlive.
But something was wrong with the script. He didn’t decline on schedule. He didn’t drag himself to that MAID appointment. He didn’t fade quietly into the category of “another inevitable loss.”
Instead, his strength crept back. His symptoms eased. And when it finally came time to check the hard data—scans, tests, numbers—the reality hit like a hammer: the man who’d been written off with stage‑four pancreatic cancer was now cancer‑free.
The tumors that were supposed to finish him were gone. The euthanasia slot that had been booked for him was empty. The medical system had prepared to manage his death, but a handful of anti‑parasitic drugs had helped him reclaim his life.
If This Is “Just Anecdotal,” Why Are They So Desperate to Shut It Down?
Mainstream defenders dismiss stories like this as “anecdotes,” as if human beings walking out of hospice‑level diagnoses don’t matter because it doesn’t fit the pharmaceutical narrative.
Yet off to the side, doctors like Dr. William Makis publicly say they’ve treated thousands of cancer patients using ivermectin, fenbendazole, and other repurposed drugs, reporting positive responses in a large share of them. At the same time, critics and media hit pieces work overtime to paint him as dangerous, fringe, even “grifting”—because nothing scares this system more than a cheap, unpatentable therapy that works too well.
And hovering over all of it is that 1951 CIA report, now finally visible, confirming that long before today’s “misinformation” hysteria, serious scientists were asking whether tumors and parasites share exploitable weaknesses—and whether parasite drugs could be turned against cancer. The CIA knew.
The scientific establishment had access to this line of thought. Yet somehow, what filtered down to regular people was a world where the only “respectable” options are the most profitable ones, and anything cheap and old is treated like a joke.
This Isn’t Just Negligence. It’s a Model.
When you stand back and look at the bigger picture, it stops looking like random oversight and starts looking like a business model.
Bury inconvenient science in classified archives. Funnel funding into patent‑ready drugs and high‑ticket technologies. Smear and silence anyone who asks why a dewormer might work on cancer. Then, when people finally dig up the old documents, call it “conspiracy theory” and insist that none of it really matters.
But it does matter—to the man who walked away from a death sentence after his family dared to try what the system refused to touch. To the thousands of patients quietly experimenting with repurposed drugs because they’ve been told “there’s nothing left to do.” And to every family who might have had more time, more options, more hope, if only the people in charge had cared more about cures than about control.
So when you hear that a 1951 CIA file has “suddenly” sparked backlash because it hints at cancer‑parasite overlap and potential treatments that never made it to the public square, understand this: the scandal isn’t just what’s in that document.
The scandal is that they had seventy‑plus years to tell you—and chose not to.
